Ani Pharmaceuticals (ANIP) Liabilities and Shareholders Equity (2010 - 2026)

Ani Pharmaceuticals has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $1.4 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 10.02% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 billion (up 17.31% YoY) and the FY2025 annual result came in at $1.4 billion, up 12.14% from the prior year.
• Liabilities and Shareholders Equity slipped to $1.4 billion in Q1 2026 per ANIP's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.4 billion in Q4 2025 and troughed at $739.1 million in Q3 2022.
• A 5-year average of $1.0 billion and a median of $914.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 60.58% in 2022, down 1.49% in 2022.
• Over 5 years, Liabilities and Shareholders Equity stood at $760.1 million in 2022, then climbed by 18.99% to $904.4 million in 2023, then surged by 42.02% to $1.3 billion in 2024, then grew by 12.14% to $1.4 billion in 2025, then dropped by 1.28% to $1.4 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.4 billion, $1.4 billion, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.